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Cardiovascular mortality is especially high among dialysis
patients with diabetes, as is morbidity due to protein energy
wasting. Given that both of these factors may be decreased
by thiazolidinedione treatment, we studied the effect of
thiazolidinedione use on survival among chronic dialysis
patients in a national cohort of 5290 incident dialysis patients
with diabetes. Thiazolidinedione use was assessed according
to prescription data, and the analyses were stratified based
on insulin use due to observed interaction. In the primary
analysis, thiazolidinedione treatment was associated with
significantly lower all-cause mortality among insulin-free but
not insulin-requiring subjects, with adjusted hazards ratios of
0.53 (0.31–0.89) and 0.82 (0.46–1.47) respectively. Sensitivity
analyses found the findings to be robust with respect to
confounding by indication, severity of the diabetes, potential
reverse causality, and time varying exposure patterns. The
mechanism of this decline in all-cause mortality will need to
be examined after these studies are confirmed.
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There are over 340,000 patients on chronic hemodialysis (HD)
in the United States; of these over 40% have diabetes (DM).1
The mortality rate among HD patients is exceedingly high
(228.9 deaths/1000 patient-years), and higher yet among those
with co-existing DM (251.4 deaths/1000 patient-years).1
Cardiovascular (CV) disease is the leading cause of death
among HD patients.2 Protein energy wasting is a potent risk
factor for death among HD patients,3 and may interact with
CV disease to portend an even graver prognosis.4 HD patients
with DM are known to be at a higher risk for CV disease and
wasting than their non-diabetic counterparts.1,2,5,6
Thiazolidinediones (TZDs) are a class of oral diabetic
medications that function by binding the peroxisome
proliferator-activated receptor g, thereby increasing insulin
sensitivity in peripheral tissues.7 Human data suggest that in
addition to lowering serum glucose, TZDs favorably alter
some CV risk factors such as increasing HDL8–17 and
circulating adiponectin,7 decreasing triglycerides,12,14–17 visc-
eral adiposity,18 circulating inflammatory mediators,19,20 and
albuminuria,8 improving flow-mediated vasodilatation,21
and blunting carotid intima-media thickening.22,23 In addi-
tion, experiments in animal models suggest that TZDs may
blunt muscle catabolism.24
Among human patients with DM and chronic kidney
disease not on HD, treatment with TZDs is associated with a
trend toward lower all-cause mortality.25 Given that suscept-
ibility to CV disease and wasting is higher among patients on
HD than among patients not yet on HD, it is plausible that
TZD treatment might be particularly effective among HD
patients. Thus, we conducted this retrospective study among
Accelerated Mortality on Renal Replacement (ArMORR)26
cohort participants with diabetes to test that hypothesis that
treatment with TZDs is associated with a decreased incidence
in all-cause mortality.
RESULTS
Description of cohort
Of 10,044 patients in the ArMORR cohort, 5290 were
diabetic and survived at least until HD day 30, and were
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included in the primary cohort. Demographic, comorbid
disease and laboratory characteristics of the cohort according
to baseline TZD and insulin exposure are given in Table 1.
Among non-insulin requiring subjects, those receiving TZDs
had significantly higher body mass indices, serum albumin
levels, and facility standardized mortality ratios than those
not receiving TZDs. Among insulin-requiring subjects, those
exposed to TZDs were significantly older than those not.
Within each insulin exposure stratum, TZD-exposed and -
unexposed subjects were otherwise similar. Pre-dialysis
random glucose levels were similar among TZD-exposed
and -unexposed patients (P¼ 0.4); glycosylated hemoglobin
levels were not available. Hemoglobin levels and equilibrated
KT/V were similar among TZD exposure groups at baseline,
and at all subsequent time points (data not shown). Serum
albumin was significantly higher among TZD-exposed
(versus unexposed) subjects at days 90 (Po0.001) and 180
(P¼ 0.05), but not at day 270 (P¼ 0.2).
Over the first month of HD, 9.6% patients were treated
with a TZD, 39.8% with insulin, and 16.9% with a
sulfonylurea (Table 2). The proportion of patients treated
with zero, one, and two or more classes of anti-diabetic
agents were 40.6, 50.2, and 9.2% respectively. b adrenergic
antagonists were prescribed in 48.8%, and antagonists of the
renin–angiotensin–aldosterone axis in 39.1%.
Baseline survival analyses
In the primary analysis, exposures were assessed over HD
days zero through 30, and survival measured following day
30 (corresponding to the start of at-risk time). A total of 719
Table 1 | Baseline characterization of subjects stratified by insulin and TZD exposure
TZD INS (n=2832) TZD+ INS (n=353) TZD INS+ (n=1953) TZD+ INS+ (n=152)
Age (years); mean (s.d.) 64.0 (13.3) 64.4 (11.8) 61.1 (13.2)* 63.9 (11.1)*
Men; n (%) 1499 (52.9%) 187 (53.0%) 1031 (52.8%) 72 (47.4%)
Non-white; n (%) 1141 (40.3%) 147 (41.6%) 722 (37.0%) 54 (35.5%)
Hypertension; n (%) 1203 (42.5%) 156 (44.2%) 827 (42.4%) 75 (49.3%)
Congestive heart failure; n (%) 409 (14.4%) 47 (13.3%) 308 (15.8%) 21 (13.8%)
Arterial disease; n (%) 480 (17.0%) 51 (14.5%) 348 (17.8%) 26 (17.1%)
Cirrhosis; n (%) 83 (2.9%) 11 (3.1%) 62 (3.2%) 4 (2.6%)
Body mass index (kg/m2); n (%) ** **
o20 233 (8.2%) 11 (3.1%) 142 (7.2%) 10 (6.6%)
20–25 836 (29.6%) 91 (25.8%) 489 (25.1%) 25 (16.6%)
25–30 826 (29.2%) 94 (26.6%) 549 (28.2%) 43 (28.5%)
30–35 464 (16.4%) 74 (21.0%) 387 (19.9%) 32 (21.2%)
435 467 (16.5%) 83 (23.5%) 380 (19.5%) 41 (27.2%)
Facility standardized mortality ratio; n (%) *** ***
o0.75 632 (22.5%) 72 (20.5%) 470 (24.3%) 39 (26.4%)
0.75–1 765 (27.2%) 112 (31.9%) 587 (30.4%) 54 (36.5%)
1–1.25 643 (22.9%) 92 (26.2%) 449 (23.2%) 25 (16.9%)
41.25 768 (27.4%) 75 (21.4%) 426 (22.1%) 30 (20.3%)
Serum albumin (g/100 ml); mean (s.d.) 3.4 (0.5)** 3.6 (0.5)** 3.4 (0.5) 3.4 (0.5)
Serum creatinine (mg/100 ml); mean (s.d.) 5.9 (2.4) 5.8 (2.4) 5.7 (2.1) 5.4(2.3)
Serum phosphate (mg/100 ml); mean (s.d.) 4.7 (1.5) 4.5 (1.5) 4.6 (1.5) 4.6 (1.6)
INS, insulin; TZD, thiazolidinedione.
*P=0.01; **Po0.001; ***P=0.03.
Table 2 | Characterization of therapies and baseline and selected follow-up time pointsa
Agent Day 0 (n=5290) Day 90 (n=4598) Day 180 (n=4180) Day 270 (n=3804)
TZD 505 (9.6%) 527 (11.5%) 557 (13.3%) 551 (14.5%)
a glucosidase inhibitor 14 (0.3%) 11 (0.2%) 12 (0.3%) 11 (0.3%)
Biguanide 19 (0.4%) 12 (0.3%) 16 (0.4%) 15 (0.4%)
Insulin 2105 (39.8%) 2155 (47.9%) 2141 (51.2%) 2009 (52.8%)
Meglitinide 140 (2.7%) 133 (2.9%) 131 (3.1%) 125 (3.3%)
Sulfonylurea 896 (16.9%) 877 (19.1%) 851 (20.1%) 813 (21.4%)
Number of classes of anti-diabetic agents
0 2150 (40.6%) 1436 (31.2%) 1098 (26.3%) 926 (24.3%)
1 2653 (50.2%) 2669 (58.1%) 2520 (60.3%) 2305 (60.6%)
42 487 (9.2%) 493 (10.7%) 562 (13.4%) 573 (15.1%)
b adrenergic antagonist 2581 (48.8%) 2599 (56.5%) 2558 (61.2%) 2404 (63.2%)
RAAS antagonist 2069 (39.1%) 2168 (47.2%) 2210 (52.9%) 2151 (56.5%)
RAAS, renin–angiotensin–aldosterone.
aReported as n (%).
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deaths occurred over 3925.3 patient-years of at-risk time;
crude mortality rate (95% CI) was 183.2 (170.3–197.1)
deaths/1000 patient-years. Median survival time was 335
days.
On bivariable analysis, the crude mortality rate was
significantly lower among TZD-exposed subjects than among
non-TZD exposed subjects: IRR (95% CI) 0.65 (0.48–0.87)
(Table 3). Survival was similar regardless of TZD agent used
(P¼ 0.45; Figure S1). The IRRs (95% CIs) for all-cause
mortality were 0.86 (0.73–1.00), 1.01 (0.82–1.22) and 1.20
(0.74–1.85) according to exposure to insulin, sulfonylureas,
and meglitinides, respectively (Table 3). The data were too
scant to examine relationships on the basis of other classes of
diabetic medications.
Stratified analysis was conducted to examine the effect
modification of the TZD – mortality association on the basis
of insulin exposure (hypothesized a priori). Among subjects
not receiving insulin, TZD exposure was associated with
reduced all-cause mortality: IRR (95% CI) 0.51 (0.33–0.74);
among subjects receiving insulin, there was no association
between TZD exposure and all-cause mortality; IRR (95%
CI) 1.03 (0.62–1.62; P for interaction¼ 0.02; Figure 1). Based
on this finding, all subsequent analyses were stratified on
insulin exposure status. (Considered alternately, the IRR
(95% CI) for insulin exposure was 0.80 (0.68–0.94) among
TZD unexposed subjects, and 1.64 (0.88–2.99) among TZD-
exposed subjects (P interaction¼ 0.02)). The association with
improved survival (among patients not on insulin) was
specific to TZDs, and was not seen with sulfonylureas or
meglitinides (Figure S2).
Cox proportional hazard models were fit to examine the
adjusted HR for all-cause mortality according to TZD
exposure status. TZD exposure was associated with adjusted
HRs (95% CIs) for all-cause mortality of 0.53 (0.31–0.89;
P¼ 0.02) and 0.82 (0.46–1.47; P40.5) among subjects not
receiving and receiving insulin, respectively (Figure 2).
Propensity score analysis yielded nearly identical results:
HRs (95% CIs) 0.48 (0.29–0.80; P¼ 0.005) and 0.79
(0.44–1.41; P¼ 0.4) for patients not receiving and receiving
insulin, respectively (Figure 2). The association with
improved survival (among patients not on insulin) was
specific to TZDs, and was not seen with sulfonylureas or
meglitinides (Table S1).
Baseline sensitivity analyses
Owing to the possibility that intensity of diabetic therapy
may have influenced findings, sensitivity analyses were
conducted in which consideration was limited to patients
on only one class of oral diabetic medication (Table 4).
Table 3 | Mortality rates and unadjusted incidence rate ratios
for all-cause mortality by diabetic treatment
Class of
agent
Mortality rate (95% CI) per 1000
patient-years
Incidence rate ratio
(95% CI)
TZD
Unexposed 189.8 (176.0–204.7) 0.65 (0.48–0.87)
Exposed 124.0 (93.7–164.1) P=0.002
Insulin
Unexposed 194.5 (177.4–213.1) 0.86 (0.73–1.00)
Exposed 166.3 (147.4–187.8) P=0.04
Sulfonylurea
Unexposed 183.0 (168.9–198.3) 1.01 (0.82–1.22)
Exposed 184.1 (154.4–219.5) P40.5
Meglitinide
Unexposed 182.3 (169.2–196.3) 1.20 (0.74–1.85)
Exposed 219.4 (143.1–336.5) P=0.4
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Figure 1 | Unadjusted mortality rate according to TZD and
insulin treatment status. Incidence rate ratios for TZD exposure
stratified by insulin exposure are given in the figure. Considered
alternately, the IRR (95% CI) for insulin exposure is 0.80 (0.68–0.94)
among TZD-unexposed subjects, and 1.64 (0.88–2.99) among TZD-
exposed subjects (P interaction¼ 0.02).
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Figure 2 | Hazard ratios for all-cause mortality according to
TZD exposure as estimated by Cox proportional hazards
models, stratified by insulin exposure status (insulin-
unexposed white, insulin-exposed gray). Multivariable models
were adjusted for age, sex, race, body mass index (categorized
r20, 20–25, 25–30, 30–35, 435), facility standardized mortality
ratio (categorizedr0.75, 0.75–1.0, 1.0–1.25, 41.25), hypertension,
arterial disease, congestive heart failure, cirrhosis, number of
classes of diabetic medications (categorized 0, 1, Z2), b
adrenergic antagonist use, renin–angiotensin–aldosterone
antagonist use, and serum albumin, creatinine, and phosphate.
Propensity score models were adjusted for the same covariates:
number of classes of diabetic medications was adjusted as a
covariate in the survival, and the remaining covariates were fit
into the propensity model.
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Among patients not receiving insulin, TZD exposure (versus
treatment with a single oral agent of another class) was
associated with an IRR (95% CI) for all-cause mortality of
0.49 (0.27–0.85); among those receiving insulin the IRR (95%
CI) was 0.80 (0.39–1.56). Diminution in the number of
outcomes prevented complete multivariable adjustment. Age
adjusted HRs (95% CIs) for all-cause mortality according to
TZD exposure were 0.56 (0.33–0.96) and 0.82 (0.43–1.55)
among patients not receiving and receiving insulin, respec-
tively. Results were similar when the comparator group was
further restricted to patients receiving single oral agent
therapy with a sulfonylurea (data not shown).
To explore whether TZDs influenced mortality through
CV mechanisms, non-CV mechanisms or both, competing
risks models were fit. Among patients not on insulin, TZDs
significantly reduced non-CV mortality, but not CV mortal-
ity: HRs (95% CIs) 0.35 (0.15–0.77) and 0.67 (0.36–1.24),
respectively (P for difference between CV and non-
CV¼ 0.002). Among subjects not on insulin, TZD exposure
did not affect either non-CV or CV mortality: HRs (95% CIs)
0.73 (0.32–1.67) and 0.88 (0.45–1.74), respectively (P for
difference between CV and non-CV mortality¼ 0.7). There
was no significant difference in the risk of CV mortality
according to TZD agent used (P rosiglitazone versus
pioglitazone¼ 0.6).
Because of the concern that we might be observing a
reverse-causal relationship (that is, that pre-terminal patients
were less likely to be exposed to TZDs), sensitivity analyses
were conducted in which exposure and outcome assessment
was lagged by 1, 2, and 3 months (Figure 3). Among patients
not receiving insulin, the multivariable adjusted HRs (95% CIs)
were 0.52 (0.30–0.90), 0.56 (0.31–1.00) and 0.63 (0.34–1.18) in
the 1, 2, and 3 month-lagged models, respectively. Estimates
were nearly identical when propensity score adjustment was
used: HRs (95% CIs) 0.47 (0.28–0.80), 0.50 (0.28–0.88), 0.56
(0.31–1.04), respectively. Among patients receiving insulin, the
corresponding adjusted HRs (95% CIs) were 0.98 (0.54–1.81),
1.14 (0.60–2.18), and 1.20 (0.61–2.36). Again, estimates were
nearly identical when propensity score adjustment was used:
HRs (95% CIs) 0.95 (0.52–1.73), 1.12 (0.59–2.14), 1.19
(0.61–2.34), respectively. Reassuringly, the point estimate for
TZD exposure was similar between baseline and lagged models,
though statistical significance was lost in the 3-month lagged
model, possibly due to diminution of the number of events.
Time-updated survival analyses
Finally, because exposure (and covariate) status may vary
over time, we fit time-updated models in which exposures
and covariates were updated at monthly intervals. Using this
approach, the adjusted odds ratio (95% CI) for all-cause
mortality according to TZD exposure was 0.64 (0.43–0.96)
among patients not on insulin, and 0.90 (0.59–1.38) among
patients on insulin (Table 5). Analogous models in which
exposure and outcome assessment lagged by 1 month yielded
nearly identical estimates.
DISCUSSION
Survival is very poor among patients on HD in general,
particularly among those with co-existing DM.1 CV disease
and protein energy wasting are potently associated with all-
cause HD-related mortality,2,3 which may be of particular
importance among diabetic patients.5,6 In addition to their
glycemic effects, TZDs have a number of pleiotropic actions
on CV risk factors and muscle wasting, suggesting that TZD
treatment might improve survival among diabetic HD
Table 4 | Results of sensitivity analyses in which single oral agent TZD exposure was compared to other single oral agent
therapy, stratified by insulin exposure
Off insulin On insulin
TZD (n=666) TZD+ (n=230) TZD (n=189) TZD+ (n=115)
Deaths/patient-years at risk 88/495.8 16/182.7 28/139.1 14/87.5
Mortality rate (95% CI); per 1000 patient-years 177.5 (144.0–218.7) 87.6 (53.7–143.0) 201.3 (139.0–291.6) 160.1 (94.8–270.3)
IRR (95%CI) all-cause mortality; TZD versus other 0.49 (0.27–0.85) 0.80 (0.39–1.56)
P=0.006 P=0.5
Age-adjusted HR (95% CI) all-cause mortality; TZD versus other 0.56 (0.33–0.96) 0.82 (0.43–1.55)
P=0.03 P40.5
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Figure 3 | Multivariable adjusted hazard ratios for all-cause
mortality according to TZD exposure in lagged analyses. In all
models, exposure was defined over days zero through 30, and
outcome assessment was lagged to varying degrees (x axis).
Separate models were fit according to insulin exposure status
(insulin-unexposed white, insulin-exposed gray). Models were
adjusted for age, sex, race, body mass index (categorized r20,
20–25, 25–30, 30–35, 435), facility standardized mortality ratio
(categorized r0.75, 0.75–1.0, 1.0–1.25, 41.25), hypertension,
arterial disease, congestive heart failure, cirrhosis, number of
classes of diabetic medications (categorized 0, 1, Z2), b
adrenergic antagonist use, renin–angiotensin–aldosterone
antagonist use, and serum albumin, creatinine, and phosphate
using Cox proportional hazards models.
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patients. Using data from a national cohort of incident HD
patients with DM, we demonstrated that among those not
receiving insulin, TZD therapy was associated with a 47%
reduction in all-cause mortality at 1 year.
To our knowledge, this is the first report of the positive
association between TZD therapy and survival among HD
patients. Clearly, if the observed association proves causal, it
would have great ramifications on survival among diabetic
patients on HD. Plausibility of the observed association is
suggested by results from a post hoc analysis of the PROactive
trial, which demonstrated that among patients with chronic
kidney disease, there was a trend towards improved survival
among those randomized to TZD therapy (HR (95% CI) 0.75
(0.55–1.03)).25 However, that trial excluded patients on HD,
in whom the benefits of TZD therapy might be expected to be
more pronounced.
The precise mechanism through which TZDs may reduce
mortality among non-insulin-dependent diabetic HD patients
is uncertain. CV disease (and attendant mortality) is highly
prevalent among HD patients, and exceeds that which would
be predicted on the basis of traditional Framingham risk
factors.27 Some of this excess risk is thought to relate, in part,
to the effects of chronic inflammation.28 Likewise, malnutri-
tion and muscle wasting are common among HD patients,29
and are potent risk factors for HD-related mortality.3 The
protein energy wasting syndrome is shown to occur as a result
of membrane-induced complement activation,30 systemic
release of inflammatory mediators,31 HD-associated nutrient
loss,32,33 and poor appetite.33 Human studies demonstrate that
diabetic HD patients have greater net loss of muscle protein
stores,5 and greater loss of lean body mass over the first year
on HD than their non-diabetic counterparts.6 Recent data
suggest that the ill-effects of CV disease and protein energy
wasting may be synergistic.4 TZDs bind PPAR g receptors,
and the resultant receptor – ligand complexes influence
transcription of a number of downstream targets.7 The net
effect is improvement in glycemic control, favorable modifica-
tion of some traditional (for example, HDL, triglycerides)8–17
and non-traditional (for example, fat distribution, circulating
inflammatory mediators, albuminuria)8,18–20 CV risk factors,
as well as decrease in insulin resistance-related muscle
catabolism and wasting.24
Our data suggest that TZDs mitigate mortality risk in
non-insulin requiring HD patients through primarily non-
CV mechanisms. Sensitivity analyses suggest a potent
association with reduced non-CV mortality, and a more
modest (and non-statistically significant) association with
reduced CV mortality. Recent reports in the literature have
suggested an association between TZDs in general, and
rosiglitazone in particular (possibly on the basis of its adverse
impacts on LDL,8–12 which are not seen with pioglita-
zone13–17,34) with increased rates of acute myocardial
infarction,35–37 and decompensated congestive heart fail-
ure.35,37 One meta-analysis suggested that rosiglitzaone was
associated with increased CV mortality;36 however, when
data from this study were re-analyzed with inclusion of three
large trials designed specifically to look at adverse CV
outcomes, this association was no longer appreciated,37
consistent with other published data.35 It is reassuring that
although our study did not detect a benefit of TZD use with
respect to CV mortality, there was no suggestion of harm
(that is, HR o1). Moreover, we did not appreciate a
differential association between individual TZDs and all-
cause or CV mortality. It must be emphasized that the
analyses of cause-specific mortality and differential effects of
individual TZDs were exploratory in nature, and should be
considered as hypothesis generating until further data
become available. Moreover, we lacked data on non-fatal
CV events, so no conclusions can be drawn regarding the
association between TZD use and non-fatal CV events in
dialysis patients.
Two observations suggest that improvement in glycemic
control is not the operative mechanism for the effects of TZD
on mortality. One, the beneficial effects on survival were
specific to TZDs, and were not seen with other classes of oral
agents, which are expected to provide similar degrees of
glycemic control.38 Two, the effects of TZDs on glycemic
control are modest (lowering hemoglobin A1c by approxi-
mately 0.6% in diabetics on HD39), and would therefore
not be expected to reduce 1-year mortality to the degree
seen.40 Regardless of the mechanism, the observed associa-
tion between TZD exposure and improved survival is
important.
These data suggest that the beneficial effects of TZDs are
limited to patients not receiving insulin. The likely explana-
tion is that exogenous insulin overwhelms insulin resistance,
thereby obviating the benefits of TZDs. However, some
proportion of insulin-treated patients were likely type I
diabetics (data on type of DM were not available), which may
have biased inference in this group. The subgroup of patients
not receiving insulin should not have included any type I
diabetics, thereby excluding the possibility that observations
in this group (including the observed reduction in all-cause
mortality related to TZD use) were biased by the type of
diabetes.
As with all observational study, there remains the
possibility of residual confounding. Specifically, one must
consider whether TZD-treated patients received these agents
Table 5 | Adjusted odds ratios (95% CI) for all-cause mortality
according to TZD exposure status estimated by time-updated
logistic regression modelsa
Un-lagged 1 Month lagged
Off insulin 0.64 (0.43–0.96) 0.63 (0.42–0.95)
P=0.03 P=0.03
On insulin 0.90 (0.59–1.38) 0.88 (0.57–1.36)
P40.5 P40.5
aAdjusted for age, race, sex, body mass index (categorizedp20, 20–25, 25–30, 30–35,
435), facility standardized mortality ratio (categorized p0.75, 0.75–1.0, 1.0–1.25,
41.25), hypertension, congestive heart failure, arterial disease, cirrhosis, number of
classes of diabetic medication (categorized 0, 1, X2), b adrenergic antagonist use,
renin–angiotensin–aldosterone antagonist use, and serum albumin, creatinine and
phosphate using time-updated logistic regression models as described in the text.
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because they: (1) were less sick or (2) were receiving better
care. With respect to question one, overall health may have
differed across TZD groups either with respect to diabetic
severity or non-diabetic illness. Assessment of diabetic
severity in HD patients is difficult. In non-HD patients one
commonly used marker is glycosylated hemoglobin level.
However, among HD patients, the utility of glycosylated
hemoglobin is limited due to shortened and variable half life
of peripheral erythrocytes;41 moreover, these data were not
available. Random, pre-dialysis glucose levels were similar
among TZD-exposed and -unexposed patients, however, the
utility of these values as markers of glycemic control is
questionable. Another marker of diabetic severity is intensity
of anti-diabetic therapy. Therefore, analyses were stratified on
the basis of insulin therapy, and further adjusted for total
number of diabetic medications. Additionally, sensitivity
analyses were conducted in which analyses were restricted to
subjects on single oral agent therapy, presuming that diabetic
severity would be similar among TZD-exposed and -
unexposed members of this subgroup, all of whom received
mono-therapy for their diabetes. Consistency of results of
this analysis with those from the primary analysis is
reassuring in this regard.
With respect to non-diabetic illness, TZD-exposed and -
unexposed patients were similar on the basis of nearly all
demographic and comorbid disease characteristics. The
exceptions were that among non-insulin-receiving subjects,
those TZD exposed had higher facility standardized mortality
ratios (which would portend a worse prognosis), serum
albumin levels and body mass indices (which would portend
a better prognosis), and among insulin-requiring subjects
those exposed to TZDs were older. Analyses were therefore
adjusted on the basis of these variables, as well as many
additional demographic, comorbid disease and laboratory
variables. In addition, propensity score models were fit to
reduce the influence of confounding by indication, and
lagged sensitivity analyses were performed to account for the
possibility that there was differential exposure to TZDs on
the basis of pre-terminal illness. Consistency of results of
these analyses with those from the primary analysis is again
reassuring.
Quality of health care was addressed in several ways. We
adjusted the analyses on the basis of facility-specific mortality
rates, as well as exposure to use of b adrenergic blockers and
antagonists of the renin–angiotensin–aldosterone axis, which
are associated with improved survival,42–44 and could have
confounded results. In addition, makers of quality of dialytic
care (hemoglobin level, equilibrated KT/V) were similar
among TZD-exposed and -unexposed patients.
As in all observational study, there was the possibility of
exposure misclassification. There was no opportunity to
assess patient adherence to medication, thus medication
exposures were based on prescription data. This approach is
consistent with intention-to-treat principles, and is con-
servative in that exposure misclassification would be expected
to bias results toward the null. In addition, because patient
exposures are not static over time, we fit time-updated
models, which reassuringly, yielded similar estimates to the
primary analysis.
Finally, this cohort consisted of diabetic patients incident
to HD. Generalization to prevalent HD patients should be
undertaken cautiously; generalization to non-diabetic HD
patients is not advisable. In addition, assessment of survival
in this study was limited to 1 year of follow up; further study
is needed to clarify longer-term effects.
We conclude that among incident hemodialysis patients
with non-insulin requiring diabetes, TZD use was associated
with significantly lower rate of all-cause mortality at 1 year of
follow up. Further studies are necessary to confirm and
generalize findings and to explore the causal nature of this
relationship.
METHODS
Study population
This protocol was approved by the University of Pennsylvania
Institutional Review Board. We conducted a retrospective analysis of
subjects in the ArMORR cohort. Details of the cohort have been
previously published.26 Briefly, the ArMORR cohort consists of all
patients incident to HD at any of over 1000 Fresenius Medical Care
units in North America (FMC-NA) between June 2004 and August
2005 (n¼ 10 044). We restricted inclusion to adult patients with
DM, as defined by (1) attribution of kidney failure to DM (Centers
for Medicare and Medicaid Services Form 2728), (2) an Interna-
tional Classification of Disease-9 code of DM upon HD initiation, or
(3) active prescription for anti-diabetic medication during the first
30 HD days. To enable baseline characterization of TZD and
covariate exposure, we further limited inclusion to subjects
surviving to HD day 31 (the start of at-risk time).
Study data
All study data were collected prospectively. Demographic and
comorbid disease characteristics were collected by study investiga-
tors at the time of HD initiation. In addition, data on each unit’s
standardized mortality ratio was collected to enable adjustment on
the basis of the ‘excellent-center effect.’ The standardized mortality
ratio is the facility-specific mortality rate relative to all other FMC-
NA units, and describes facility-level mortality beyond what would
be expected on the basis of age, race, gender, nutritional status, and
HD adequacy. All laboratory tests were performed in a centralized
laboratory (Spectra Laboratories, Rockleigh, NJ, USA).
Medication data were collected at baseline, and subsequently
updated at each dialysis session. No opportunity existed to assess
medication adherence, thus patients were classified as exposed if
they had an active prescription spanning that treatment. TZD
exposure was considered to be an active prescription for either
rosiglitazone (Avandia, Glaxo Smith Kline) or pioglitazone (Actos,
Takeda Pharmaceutical Company Ltd.). For the purpose of analysis,
medication exposure was considered monthly: a patient was
considered to be exposed if he/she had an active prescription for
that medication any time during the month.
The primary outcome of interest was time to death from any
cause. Subjects were followed prospectively until they died or were
censored at the time of transfer of care away from FMC-NA,
recovery of kidney function, renal transplantation, or change in
dialytic modality. As of the time of these analyses, complete
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outcome data were available through 1 year, thus subjects were
administratively censored at this time point.
In the primary analyses, exposure was defined over the first 30
days following the onset of chronic HD. Exposure to TZDs was then
related to survival beginning on 31st day after the onset of HD
(corresponding to the start of at-risk time) and continuing until
death or censoring.
Statistical analysis
Continuous data were analyzed graphically and by calculation of
summary statistics. Between-group comparisons were conducted using
the Student’s t-test. Categorical data were analyzed in terms of counts
and proportions, and compared using the w2 Test. In bivariable
analyses, survival was compared among groups by calculation of
stratum specific (for example, TZD exposed, unexposed) mortality
rates, and estimation of incidence rate ratios (IRRs). Pre-specified
interaction of the TZD – mortality association on the basis of insulin
exposure status was examined using stratified analysis and Mantel–-
Haenzel methods. Given the potent interaction identified, all
subsequent analyses were stratified on the basis of insulin treatment.
Adjusted hazard ratios (HRs) were estimated using Cox proportional
hazards models, which included terms for pre-specified demographic,
comorbid disease, laboratory, and medication covariates of interest.
Separate models were fit for insulin-exposed and -unexposed patients.
The proportional hazards assumption was tested graphically and by
inclusion of two-way cross product terms with time. To account for
potential confounding by indication, propensity score adjustment was
used. Propensity models were specified as logistic regression models
with TZD exposure as the response variable and covariates (aside from
number of classes of diabetic medication) as predictor variables.
Association between TZD and outcome was assessed using propor-
tional hazards models with covariate terms for propensity score (as a
continuous variable; linearity assumption tested graphically) and
number of classes of diabetic medication.
The effect of TZD use on cause-specific mortality (that is, CV,
non-CV) was examined using competing risks models. These models
were specified according to the method of Lunn.45 Cause of death
was adjudicated by International Classification of Disease-9 code (list
given in Supplementary Table S2, Supplementary Materials). A series
of lagged analyses was performed in which TZD (and covariate)
exposure over HD days zero through 30 was used to predict survival
beginning on HD days 61, 91, and 121. Methods were otherwise
analogous to those used in the primary analyses.
Finally, we conducted analyses using time-updated exposure and
covariate data. In these models, each patient’s experience was
decomposed into individual patient-months. Time-updated logistic
regression models were fit such that survival in month t was
predicted on the basis of exposures in month t1. Analyses were
stratified on insulin status by inclusion of a two-way cross product
term with TZD exposure. Robust variance estimates were used to
correct for non-independence of observations within patient.
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